[1]高兰,黄哲凯,寇俊萍,等.脂肪因子在心血管疾病中的研究进展[J].陕西医学杂志,2026,(4):561-565,571.[doi:DOI:10.3969/j.issn.1000-7377.2026.04.023]
　GAO Lan,HUANG Zhekai,KOU Junping,et al.Research progress on the role of adipokines in cardiovascular diseases[J].,2026,(4):561-565,571.[doi:DOI:10.3969/j.issn.1000-7377.2026.04.023]
点击复制

脂肪因子在心血管疾病中的研究进展

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年4期
页码:
561-565,571
栏目:
综述
出版日期:
2026-04-05

文章信息/Info

Title:
Research progress on the role of adipokines in cardiovascular diseases
作者:
高兰1; 黄哲凯2; 寇俊萍2; 李芳1; 2
（1.中国药科大学附属江宁中医院 南京市江宁中医院，江苏 南京 211198；2.中国药科大学中药学院中药药理与中医药学系，江苏 南京 211198）
Author(s):
GAO Lan1 ; HUANG Zhekai2; KOU Junping2; LI Fang1; 2
（1.Affiliated Jiangning Hospital of Chinese Medicine,School of Traditional Chinese Pharmacy,China Pharmaceutical University,Nanjing 211198,China；2.School of Traditional Chinese Pharmacy,China Pharmaceutical University,Nanjing 211198,China）
关键词:
脂肪因子; 代谢性心血管疾病; 动脉粥样硬化; 心肌缺血再灌注; 心肌病; 心律失常; 心脏瓣膜病; 慢性心力衰竭
Keywords:
Adipokines; Cardiometabolic diseases; Atherosclerosis; Myocardial ischemiareperfusion; Cardiomyopathy; Arrhythmia; Valvular heart disease; Chronic heart failure
分类号:
R 543
DOI:
DOI:10.3969/j.issn.1000-7377.2026.04.023
文献标志码:
A
摘要:
心血管疾病是全球死亡的主要原因，其发病机制复杂，与炎症反应、氧化应激、内皮功能障碍等多种因素密切相关。脂肪因子是由脂肪组织产生和释放的重要激素，已有研究表明脂肪因子通过多靶点多途径影响心血管疾病发生发展。心肌脂肪组织存在串扰通路，通过靶向脂肪因子治疗心血管疾病相较传统药物治疗更具优势。从心肌脂肪组织相互作用角度出发可为心血管疾病临床治疗提供新思路。现对脂肪因子在心血管疾病方面作用进行综述，以期为防治心血管疾病提供科学参考。
Abstract:
Cardiovascular diseases remain a leading cause of global mortality,with their pathogenesis intricately associated with multiple interrelated factors including inflammatory responses,oxidative stress,and endothelial dysfunction.Adipokines,critical bioactive mediators produced and secreted by adipose tissue,have been shown to regulate the pathogenesis and progression of cardiovascular diseases through multitarget mechanisms.The presence of crosstalk pathways between cardiac and adipose tissues demonstrates that adipokinetargeted therapies exhibit significant advantages over conventional pharmacological treatments in cardiovascular diseases.Investigating cardiacadipose tissue interactions provides innovative perspectives for the clinical treatment of cardiovascular diseases.This article reviews the role of adipokines in cardiovascular diseases,and providing scientific reference for the prevention and treatment of cardiovascular diseases.

参考文献/References:

[1]MARTIN S S,ADAY A W,ALLEN N B,et al.2025 heart disease and stroke statistics：A report of US and global data from the american heart association[J].Circulation,2025,151（8）：e641-e660.
[2]NIELSEN M B,COLAK Y,BENN M,et al.Plasma adiponectin levels and risk of heart failure,atrial fibrillation,aortic valve stenosis,and myocardial infarction：Large-scale observational and Mendelian randomization evidence[J].Cardiovasc Res,2024,120（1）：95-107.
[3]CHOW L S,GERSZTEN R E,TAYLOR J M,et al.Exerkines in health,resilience and disease[J].Nat Rev Endocrinol,2022,18（5）：273-289.
[4]TILG H,IANIRO G,GASBARRINI A,et al.Adipokines：Masterminds of metabolic inflammation[J].Nat Rev Immunol,2025,25（4）：250-265.
[5]GIANOPOULOS I,MANTZOROS C S,DASKALOPOULOU S S.Adiponectin and adiponectin receptors in atherosclerosis[J].Endocr Rev,2025,46（1）：1-25.
[6]RANA M N,NEELAND I J.Adipose tissue inflammation and cardiovascular disease：An update[J].Curr Diab Rep,2022,22（1）：27-37.
[7]唐平,赵洪磊,阎德文.代谢性心血管疾病基层综合防控专家共识[J].心血管病防治知识,2024,14（18）：3-13.
[8]TAN L,LU X,DANSER A H J,et al.The role of chemerin in metabolic and cardiovascular disease：A literature review of its physiology and pathology from a nutritional perspective[J].Nutrients,2023,15（13）：2878.
[9]HARRISON S A,ROLPH T,KNOTT M,et al.FGF21 agonists：An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond[J].J Hepatol,2024,81（3）：562-576.
[10]ZABETIAN-TARGHI F,MAHMOUDI M J,REZAEI N,et al.Retinol binding protein 4 in relation to diet,inflammation,immunity,and cardiovascular diseases[J].Adv Nutr,2021,6（6）：748-762.
[11]YE X,WANG Z,LEI W,et al.Pentraxin 3：A promising therapeutic target for cardiovascular diseases[J].Ageing Res Rev,2024,93：102163.
[12]KIM J E,KIM J S,JO M J,et al.The roles and associated mechanisms of adipokines in development of metabolic syndrome[J].Molecules,2022,27（2）：334-343.
[13]HEO Y J,CHOI S E,JEON J Y,et al.Visfatin induces inflammation and insulin resistance via the NF-κB and STAT3 signaling pathways in hepatocytes[J].J Diabetes Res,2019,2019：4021623.
[14]WATANABE T,KAHO W T,TAKAHASHI Y,et al.Adipose tissue-derived omentin-1 function and regulation[J].Compr Physiol,2017,7（3）：765-781.
[15]ZENG Q,SONG J,SUN X,et al.A negative feedback loop between TET2 and leptin in adipocyte regulates body weight[J].Nat Commun,2024,15（1）：2825.
[16]张国安,石践,宋宝国,等.囊泡相关膜蛋白8通过激活AMP活化蛋白激酶/哺乳动物雷帕霉素靶蛋白介导自噬促进动脉粥样硬化研究[J].陕西医学杂志,2025,54（7）：899-907，924.
[17]饶嘉,林妙,胡江.TyG指数和UHR、PLR水平对2型糖尿病患者颈动脉粥样硬化的预测价值[J].空军军医大学学报,2024,45(12):1441-1445.
[18]ANTONIADES C,TOUSOULIS D,VAVLUKIS M,et al.Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers[J].Eur Heart J,2023,44（38）：3827-3844.
[19]XIA N,HORKE S,HABERMEIER A,et al.Uncoupling of endothelial nitric oxide synthase in perivascular adipose tissue of diet-induced obese mice[J].Arterioscler Thromb Vasc Biol,2016,36（1）：78-85.
[20]VACEK T P,REHMAN S,NEAMTU D,et al.Matrix metalloproteinases in atherosclerosis：Role of nitric oxide,hydrogen sulfide,homocysteine,and polymorphisms[J].Vasc Health Risk Manag,2015,11：173-183.
[21]RAMI A Z A,HAMID A A,ANUAR N N M,et al.Exploring the relationship of perivascular adipose tissue inflammation and the development of vascular pathologies[J].Mediators Inflamm,2022,2022：2734321.
[22]HIRAMATSU-ITO M,SHIBATA R,OHASHI K,et al.Omentin attenuates atherosclerotic lesion formation in apolipoprotein E-deficient mice[J].Cardiovasc Res,2016,110（1）：107-117.
[23]HUANG C,ZHANG P,LI T,et al.Overexpression of CTRP9 attenuates the development of atherosclerosis in apolipoprotein E-deficient mice[J].Mol Cell Biochem,2019,455（1-2）：99-108.
[24]ZHANG H,GONG X,NI S,et al.C1q/TNF-related protein-9 attenuates atherosclerosis through AMPK-NLRP3 inflammasome singling pathway[J].Int Immunopharmacol,2019,77：105934.
[25]MAHADEV K,WU X,DONNELLY S,et al.Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cells[J].Cardiovasc Res,2008,78（2）：376-384.
[26]CHO Y,LEE S E,LEE H C,et al.Adipokine resistin is a key player to modulate monocytes,endothelial cells,and smooth muscle cells,leading to progression of atherosclerosis in rabbit carotid artery[J].J Am Coll Cardiol,2021,57（1）：99-109.
[27]MASTOOR Y,MURPHY E,ROMAN B.Mechanisms of postischemic cardiac death and protection following myocardial injury[J].J Clin Invest,2025,135（1）：e184134.
[28]赵明慧,薛凌.毛蕊异黄酮靶向高迁移率族蛋白1对心肌缺血再灌注损伤大鼠保护作用实验研究[J].陕西医学杂志,2024,53（7）：873-878，883.
[29]GAN L,LIU D,XIE D,et al.Ischemic heart-derived small extracellular vesicles impair adipocyte function[J].Circ Res,2022,130（1）：48-66.
[30]GAN L,ZHAO J,YAO P,et al.Adipocyte-derived small extracellular vesicles exacerbate diabetic ischemic heart injury by promoting oxidative stress and mitochondrial-mediated cardiomyocyte apoptosis[J].Redox Biol,2025,79：103443.
[31]SHIBATA R,SATO K,PIMENTEL D R,et al.Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK-and COX-2-dependent mechanisms[J].Nat Med,2005,11（10）：1096-1103.
[32]TAO L,GAO E,JIAO X,et al.Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress[J].Circulation,2007,115（11）：1408-1416.
[33]张书敏,蔡尚郎,刘晓飞,等.原发性扩张型心肌病患者血浆网膜素-1和脂联素水平变化及意义[J].临床心血管病杂志,2016,32（2）：139-142.
[34]DILLMANN W H.Diabetic cardiomyopathy[J].Circ Res,2019,124（8）：1160-1162.
[35]BELLEMARE M,BOURCIER L,IGLESIES-GRAU J,et al.Mechanisms of diabetic cardiomyopathy：Focus on inflammation[J].Diabetes Obes Metab,2025:1-13.
[36]ZENG H,HE X,HOU X,et al.Apelin gene therapy increases myocardial vascular density and ameliorates diabetic cardiomyopathy via upregulation of sirtuin 3[J].Am J Physiol Heart Circ Physiol,2014,306（4）：585-597.
[37]LI B,YIN J,CHANG J,et al.Apelin/APJ relieve diabetic cardiomyopathy by reducing microvascular dysfunction[J].J Endocrinol,2021,249（1）：1-18.
[38]LI X,KE X,LI Z,et al.Vaspin prevents myocardial injury in rats model of diabetic cardiomyopathy by enhancing autophagy and inhibiting inflammation[J].Biochem Biophys Res Commun,2019,514（1）：1-8.
[39]MA Z G,YUAN Y P,XU S C,et al.CTRP3 attenuates cardiac dysfunction,inflammation,oxidative stress and cell death in diabetic cardiomyopathy in rats[J].Diabetologia,2017,60（6）：1126-1137.
[40]ZHAO B,BOUCHAREB R,LEBECHE D.Resistin deletion protects against heart failure injury by targeting DNA damage response[J].Cardiovasc Res,2021,29：18234.
[41]CHEMALY E R,KANG S,ZHANG S,et al.Differential patterns of replacement and reactive fibrosis in pressure and volume overload are related to the propensity for ischaemia and involve resistin[J].J Physiol,2021,591（21）：5337-5355.
[42]LI H,YAO W,IRWIN M G,et al.Adiponectin ameliorates hyperglycemia-induced cardiac hypertrophy and dysfunction by concomitantly activating Nrf2 and Brg1[J].Free Radic Biol Med,2015,84：311-321.
[43]IACOBELLIS G.Epicardial adipose tissue in contemporary cardiology[J].Nat Rev Cardiol,2022,19（9）：593-606.
[44]MAO Y,ZHAO K,LI P,et al.The emerging role of leptin in obesity-associated cardiac fibrosis：Evidence and mechanism[J].Mol Cell Biochem,2023,478（5）：991-1011.
[45]LI G,YANG J,ZHANG D,et al.Research progress of myocardial fibrosis and atrial fibrillation[J].Front Cardiovasc Med,2022,9：889706.
[46]FAN Y,HUANG S,LI S,et al.The adipose-neural axis is involved in epicardial adipose tissue-related cardiac arrhythmias[J].Cell Rep Med,2024,5（5）：101559.
[47]SCARANO PEREIRA J P,OWEN E,MARTININO A,et al.Epicardial adipose tissue,obesity,and the occurrence of atrial fibrillation：An overview of pathophysiology and treatment methods[J].Expert Rev Cardiovasc Ther,2022,20（4）：307-322.
[48]MANZOOR F.Association of adiponectin gene expression with atrial fibrillation in a Pakistani populace[J].Sci Rep,2023,13（1）：22589.
[49]LI B,PO S S,ZHANG B,et al.Metformin regulates adiponectin signalling in epicardial adipose tissue and reduces atrial fibrillation vulnerability[J].J Cell Mol Med,2020,24（14）：7751-7766.
[50]CONTE M,PETRAGLIA L,CABARO S,et al Epicardial adipose tissue and cardiac arrhythmias：Focus on atrial fibrillation[J].Front Cardiovasc Med,2022,9：932262.
[51]刘倩,韩丹,王飞扬,等.频发室性早搏与心脏瓣膜手术同期迷宫手术后心房颤动复发关系研究[J].陕西医学杂志,2024,53（9）：1215-1219.
[52]LEE S H,KIM N,KIM M,et al.Single-cell transcriptomics reveal cellular diversity of aortic valve and the immunomodulation by PPARγ during hyperlipidemia[J].Nat Commun,2022,13（1）：5461.
[53]BORTNICK A E,AUSTIN T R,HAMERTON E,et al.Plasma proteomic assessment of calcific aortic valve disease in older adults[J].J Am Heart Assoc,2025,14（5）：e036336.
[54]MONCLA L M,BRIEND M,BOSS Y,et al.Calcific aortic valve disease：Mechanisms,prevention and treatment[J].Nat Rev Cardiol,2023,20（8）：546-559.
[55]ROSA M,PARIS C,SOTTEJEAU Y,et al.Leptin induces osteoblast differentiation of human valvular interstitial cells via the Akt and ERK pathways[J].Acta Diabetol,2017,54（6）：551-560.
[56]CREA F.Epidemiology and treatment of acute and chronic heart failure[J].Eur Heart J,2023,44（5）：329-332.
[57]VAN VELDHUISEN S L,GORTER T M,VAN WOERDEN G,et al.Bariatric surgery and cardiovascular disease：A systematic review and meta-analysis[J].Eur Heart J,2022,43（20）：1955-1969.
[58]SUNDSTROM J,BRUZE G,OTTOSSON J,et al.Weight loss and heart failure：A nationwide study of gastric bypass surgery versus intensive lifestyle treatment[J].Circulation,2017,135（17）：1577-1585.
[59]YANG H H,WANG X,LI S,et al.Lipocalin family proteins and their diverse roles in cardiovascular disease[J].Pharmacol Ther,2023,244：108385.
[60]LI X Z,ZHANG K Z,YAN J J,et al.Serum retinol-binding protein 4 as a predictor of cardiovascular events in elderly patients with chronic heart failure[J].ESC Heart Fail,2020,7（2）：542-550.
[61]LIU D,GU G,GAN L,et al.Identification of a CTRP9 C-Terminal polypeptide capable of enhancing bone-derived mesenchymal stem cell cardioprotection through promoting angiogenic exosome production[J].Redox Biol,2021,41：101929.
[62]WANG W W,JI S Y,ZHANG W,et al.Structure-based design of non-hypertrophic apelin receptor modulator[J].Cell,2024,187（6）：1460-1475.
[63]GARGALOVIC P,WONG P,ONORATO J,et al.In vitro and in vivo evaluation of a small-molecule APJ （apelin receptor） agonist,BMS-986224,as a potential treatment for heart failure[J].Circ Heart Fail,2021,14（3）：e007351.
[64]TAN W,WANG Y,CHENG S,et al.Adipo ron ameliorates the progression of heart failure with preserved ejection fraction via mitigating lipid accumulation and fibrosis[J].J Adv Res,2025,68：299-315.
[65]HUBY A C,ANTONOVA G,GROENENDYK J,et al.Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion,which promotes endothelial dysfunction and cardiac fibrosis[J].Circulation,2015,132（22）：2134-2145.
[66]PACKER M.Leptin-aldosterone-neprilysin axis：Identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity[J].Circulation,2018,137（15）：1614-1631.
[67]KAMAREDDINE L,GHANTOUS C M,ALLOUCH S,et al.Between inflammation and autophagy：The role of leptin-adiponectin axis in cardiac remodeling[J].J Inflamm Res,2021,14：5349-5365.

相似文献/References:

[1]焦文妤,尚家璐,李树霞△.慢性阻塞性肺疾病患者血清补体C1q肿瘤坏死因子相关蛋白5与肺功能及炎症反应相关性研究[J].陕西医学杂志,2019,(12):1616.

备注/Memo

备注/Memo:
国家自然科学基金资助项目（82274231,81973506）；中国药科大学附属江宁中医院科研项目资助（YJZD2025009）
更新日期/Last Update: 2026-04-05